Literature DB >> 19318621

Challenges and opportunities in defining the essential cancer kinome.

Brendan D Manning1.   

Abstract

Signaling pathways controlled by protein kinases underlie a large fraction of human diseases and participate in the development and progression of all forms of cancer. Targeted therapeutic strategies to treat cancer and other diseases are focused almost exclusively on protein kinases, with a strong bias toward a small subset of the entire human kinome. RNA interference (RNAi)-based screens for protein kinase requirements have revealed a surprisingly high degree of diversity between cancer cell lines in their dependence on specific protein kinases. These screens also demonstrate that some of the most critical protein kinases for the proliferation and survival of cancer cell lines are also the least studied. Although the concept of oncogene addiction is powerful in designing therapeutic strategies to treat cancer, unbiased kinome-specific and genome-wide RNAi screens are revealing unexploited areas of potential therapeutic intervention.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19318621     DOI: 10.1126/scisignal.263pe15

Source DB:  PubMed          Journal:  Sci Signal        ISSN: 1945-0877            Impact factor:   8.192


  20 in total

1.  The role of p27(Kip1) in dasatinib-enhanced paclitaxel cytotoxicity in human ovarian cancer cells.

Authors:  Xiao-Feng Le; Weiqun Mao; Guangan He; Francois-Xavier Claret; Weiya Xia; Ahmed Ashour Ahmed; Mien-Chie Hung; Zahid H Siddik; Robert C Bast
Journal:  J Natl Cancer Inst       Date:  2011-08-02       Impact factor: 13.506

2.  The (un)targeted cancer kinome.

Authors:  Oleg Fedorov; Susanne Müller; Stefan Knapp
Journal:  Nat Chem Biol       Date:  2010-03       Impact factor: 15.040

Review 3.  Protein kinase signaling networks in cancer.

Authors:  John Brognard; Tony Hunter
Journal:  Curr Opin Genet Dev       Date:  2010-11-29       Impact factor: 5.578

4.  Inhibition of polo-like kinase 1 in glioblastoma multiforme induces mitotic catastrophe and enhances radiosensitisation.

Authors:  Anita T Tandle; Tamalee Kramp; Whoon J Kil; Aditya Halthore; Kristen Gehlhaus; Uma Shankavaram; Philip J Tofilon; Natasha J Caplen; Kevin Camphausen
Journal:  Eur J Cancer       Date:  2013-06-18       Impact factor: 9.162

5.  Genetically encoded fluorescent reporters to visualize protein kinase C activation in live cells.

Authors:  Lisa L Gallegos; Alexandra C Newton
Journal:  Methods Mol Biol       Date:  2011

6.  Interrogating the hidden phosphoproteome.

Authors:  Un-Beom Kang; William M Alexander; Jarrod A Marto
Journal:  Proteomics       Date:  2017-03       Impact factor: 3.984

7.  Phosphoproteomic analysis of leukemia cells under basal and drug-treated conditions identifies markers of kinase pathway activation and mechanisms of resistance.

Authors:  Maria P Alcolea; Pedro Casado; Juan-Carlos Rodríguez-Prados; Bart Vanhaesebroeck; Pedro R Cutillas
Journal:  Mol Cell Proteomics       Date:  2012-04-29       Impact factor: 5.911

Review 8.  Association of survivin splice variants with prognosis and treatment of breast cancer.

Authors:  Anastasia Pavlidou; Christos Kroupis; Kleanthi Dimas
Journal:  World J Clin Oncol       Date:  2014-12-10

9.  Phosphoproteomics by mass spectrometry: insights, implications, applications and limitations.

Authors:  Viveka Mayya; David K Han
Journal:  Expert Rev Proteomics       Date:  2009-12       Impact factor: 3.940

Review 10.  Targeting the cancer kinome through polypharmacology.

Authors:  Zachary A Knight; Henry Lin; Kevan M Shokat
Journal:  Nat Rev Cancer       Date:  2010-02       Impact factor: 60.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.